Rachel is a highly experienced government relations and legislative affairs strategist and advocate who is informed by a solid foundation of health policy knowledge.
Prior to joining McDermottPlus, Rachel served as the director of policy and government relations for a health IT contractor, where she developed the company’s first strategic plan for government relations. She grew the company’s profile on Capitol Hill by establishing new relationships with key leaders in the federal, state and military health program space. As a result, the company became an authoritative source on a variety of legislative approaches, especially related to veterans’ health.
Prior to that role, Rachel was lead legislative liaison at the US Department of Health and Human Services’ Office of the National Coordinator for Health IT (ONC) where she was instrumental in providing research, analysis and feedback to Members of Congress and staff on the 21st Century Cures legislation, among other relevant policies. Rachel also created short- and long-term strategic outreach plans that increased ONC’s visibility and profile.
Earlier in her career, Rachel served in several senior health legislative roles in the personal offices of Members of Congress, including most notably Congresswoman Diana DeGette. She was the primary staff for a variety of health policy issues, such as diabetes, medical research, drug and medical device development, data sharing and privacy, mental health and health IT, and was a lead staffperson creating and driving the 21st Century Cures Act. In these roles, Rachel engaged with many external stakeholders to advance legislative and regulatory challenges and coordinate action on items such as legislation, hearings, briefings, and letters to congressional leadership and the administration.
Served as lead health policy staff for several Members of Congress, with a focus on advancing legislative priorities through key alliances with other members and relationships with external stakeholders
Led several strategic planning efforts focusing on building and maintaining relationships with members and staff in order to increase profiles and presence on Capitol Hill and serve as authoritative sources on related health policy
“CMS Take Steps to Modernize Clinical Lab Policies,” McDermott Will & Emery LLP On the Subject, Paul Radensky, M.D., John Warren and Eric Zimmerman, February 11, 2014.
6 New Medicare Proposals Firing Up Docs, Hospitals Law360, September 16, 2013
Paul Radensky, commenting on surgeon complaints that Medicare’s proposed rule to create packages of payments for various tests, procedures, drugs and supplies would dissuade them from using products that are more expensive even if they’re also more effective, said that many of his clients are spooked by the plan. “When you talk to the clinicians who treat these patients, they will tell you that the products are not [equal],” Mr. Radensky said.
5 Must-Watch Issues For Health Cos. In 2013’s Home Stretch Law360, September 13, 2013
Eric Zimmerman said of impending cuts in Medicare reimbursement to critical access hospitals and many providers of post-acute care, “It’s these things that have been out there for a while and have the president’s endorsement that are the most vulnerable.” Regarding another possible reimbursement cut to a variety of medical service providers, Paul Radensky described his specialty lab clients as “very concerned about this proposal.” Noting the need to revise Medicare reimbursement codes, Mr. Radensky added: “I think everybody agrees there are a whole lot of things that are around that weren’t around in the 1980s. The concern is the details.”
Do not send any information or documents that you want to have treated as secret or confidential. Providing information to McDermott via email links on this website or other introductory email communications will not create an attorney-client relationship; will not preclude McDermott from representing any other person or firm in any matter; and will not obligate McDermott to keep confidential the information you provide. McDermott cannot enter into an attorney-client relationship with you until McDermott has determined that doing so will not create a conflict of interest and until you and McDermott have entered into a written agreement or engagement letter that sets forth the terms of our relationship.